To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Alpha emitter radium-223 … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Alpha emitter radium-223 and survival in metastatic prostate cancer.

Journal article
Authors C Parker
S Nilsson
D Heinrich
S I Helle
J M O'Sullivan
S D Fosså
A Chodacki
P Wiechno
J Logue
M Seke
A Widmark
D C Johannessen
P Hoskin
D Bottomley
N D James
A Solberg
I Syndikus
J Kliment
S Wedel
S Boehmer
M Dall'Oglio
L Franzén
R Coleman
N J Vogelzang
C G O'Bryan-Tear
K Staudacher
J Garcia-Vargas
M Shan
Ø S Bruland
O Sartor
Jon Kindblom
Published in The New England journal of medicine
Volume 369
Issue 3
Pages 213-23
ISSN 1533-4406
Publication year 2013
Published at
Pages 213-23
Language en
Keywords Aged, Aged, 80 and over, Bone Neoplasms, mortality, radiotherapy, secondary, Double-Blind Method, Humans, Isotopes, Kaplan-Meier Estimate, Male, Middle Aged, Prostatic Neoplasms, mortality, pathology, radiotherapy, Radium, adverse effects, therapeutic use
Subject categories Cancer and Oncology


Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?